Absci Q3 revenue misses estimates, net loss widens on R&D spending
ABSI•Absci reported Q3 revenue of $304,000, below the $727,130 estimate, and a net loss of $33.30 million as research and development expenses rose.
1. Quarterly results
Absci's Q3 revenue was $304,000, missing the $727,130 consensus estimate from eight analysts. The company reported a net loss of $33.30 million, operating expenses of $35.30 million and a loss per basic share of $0.19.
2. Costs and pipeline
Research and development expenses rose mainly due to advancement of internal programs, including direct costs for ABS-201 clinical and nonclinical development. Absci expects 13-week interim proof-of-concept data for ABS-201 in PHL in December 2026, followed by full 26-week data in early 2027, and plans to start a Phase 2 endometriosis trial in mid-2027. The company appointed Gerry Muhle as chief commercial officer.
